These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. New and Old Horizons for an Ancient Drug: Pharmacokinetics, Pharmacodynamics, and Clinical Perspectives of Dimethyl Fumarate. Matteo P; Federico D; Emanuela M; Giulia R; Tommaso B; Alfredo G; Anna C; Annamaria O Pharmaceutics; 2022 Dec; 14(12):. PubMed ID: 36559226 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of dimethyl fumarate in ALS: randomised controlled study. Vucic S; Henderson RD; Mathers S; Needham M; Schultz D; Kiernan MC; Ann Clin Transl Neurol; 2021 Oct; 8(10):1991-1999. PubMed ID: 34477330 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial. Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J Lancet Neurol; 2022 Aug; 21(8):693-703. PubMed ID: 35841908 [TBL] [Abstract][Full Text] [Related]
7. Dimethyl fumarate for multiple sclerosis. Xu Z; Zhang F; Sun F; Gu K; Dong S; He D Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD011076. PubMed ID: 25900414 [TBL] [Abstract][Full Text] [Related]
8. Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis. Norborg H; Riise T; Myhr KM; Grytten N; Wergeland S Mult Scler J Exp Transl Clin; 2021; 7(2):20552173211022027. PubMed ID: 34188949 [TBL] [Abstract][Full Text] [Related]
9. A Bibliometric Evaluation of the Top 100 Cited Dimethyl Fumarate Articles. García-Fernández FJ; García-Fernández AE; Ikuta I; Nava E; Solis García Del Pozo J; Jordan J; Galindo MF Molecules; 2021 Feb; 26(4):. PubMed ID: 33669498 [TBL] [Abstract][Full Text] [Related]
10. COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy. Jaber A; Patel M; Sylvester A; Yarussi M; Kalina JT; Mendoza JP; Avila RL; Tremblay MA Neurol Ther; 2023 Apr; 12(2):687-700. PubMed ID: 36792812 [TBL] [Abstract][Full Text] [Related]
11. Management Strategies to Facilitate Optimal Outcomes for Patients Treated with Delayed-release Dimethyl Fumarate. Mayer L; Fink MK; Sammarco C; Laing L Drug Saf; 2018 Apr; 41(4):347-356. PubMed ID: 29218681 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Delayed-Release Dimethyl Fumarate in Pediatric Patients With Relapsing Multiple Sclerosis (FOCUS). Alroughani R; Das R; Penner N; Pultz J; Taylor C; Eraly S Pediatr Neurol; 2018 Jun; 83():19-24. PubMed ID: 29681490 [TBL] [Abstract][Full Text] [Related]
13. Dimethyl fumarate (Tecfidera): a new oral agent for multiple sclerosis. Venci JV; Gandhi MA Ann Pharmacother; 2013 Dec; 47(12):1697-702. PubMed ID: 24259625 [TBL] [Abstract][Full Text] [Related]
14. Dimethyl Fumarate: A Review in Relapsing-Remitting MS. Blair HA Drugs; 2019 Dec; 79(18):1965-1976. PubMed ID: 31784875 [TBL] [Abstract][Full Text] [Related]
15. Stability indicating RP-HPLC method for determination of dimethyl fumarate in presence of its main degradation products: Application to degradation kinetics. Habib AA; Hammad SF; Amer MM; Kamal AH J Sep Sci; 2021 Feb; 44(3):726-734. PubMed ID: 33253476 [TBL] [Abstract][Full Text] [Related]
16. Dimethyl fumarate ameliorates hepatic inflammation in alcohol related liver disease. Sangineto M; Grabherr F; Adolph TE; Grander C; Reider S; Jaschke N; Mayr L; Schwärzler J; Dallio M; Moschen AR; Moschetta A; Sabbà C; Tilg H Liver Int; 2020 Jul; 40(7):1610-1619. PubMed ID: 32306456 [TBL] [Abstract][Full Text] [Related]
17. Diroximel Fumarate as a Novel Oral Immunomodulating Therapy for Relapsing Forms of Multiple Sclerosis: A Review on the Emerging Data. Hauer L; Sellner J Drug Des Devel Ther; 2022; 16():3915-3927. PubMed ID: 36388086 [TBL] [Abstract][Full Text] [Related]
18. Impact of treatment with dimethyl fumarate on sleep quality in patients with relapsing-remitting multiple sclerosis: A multicentre Italian wearable tracker study. Comi G; Leocani L; Ferini-Strambi L; Radaelli M; Costa GD; Lanzillo R; Lus G; Bianchi V; Traccis S; Capone F; Grimaldi LM; Salemi G; Cardillo A; Zipoli V; Mult Scler J Exp Transl Clin; 2023; 9(1):20552173221144229. PubMed ID: 36776745 [TBL] [Abstract][Full Text] [Related]